With the acquisition process underway, both Intas Biopharma and Biologics Process Development (BPD) are actively pursuing plans to work closely toward fulfillment of common business objectives in the area of biologics contract research and manufacturing services (CRAMS).
This development will facilitate and assist Intas Biopharma’s foray into the US market especially to expand its CRAMS business. With mutual understanding and agreement between the two companies, Scott Brown, founder, president and chief scientific officer of BPD will continue as president and chief scientific officer.
Dr Brown said: “We are pleased to become associates with Intas Biopharmaceuticals, a leader in the area of biologics research and manufacturing in India. Jointly we complement each other on the technology front, and we at BPD are looking forward to working with Intas and exploring new technology frontiers.”